Serum Trace Element Levels in Some Gynecological Diseases

NCT07210918 | Completed

• 1 other identifier: Cütam Dilara
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this clinical study is to measure the levels of various trace elements in the blood serum of women with various gynecological diseases and to compare them with healthy controls. The main questions it aims to answer are:

• Do trace element levels increase or decrease in endometriosis?
• Do trace element levels increase or decrease in ovarian cancer patients?
• Do trace element levels increase or decrease in endometrial cancer patients? Participants: Each member of the study group will visit the clinic only once and donate 5 ml of blood.

Conditions

Endometriosis; Endometrial Cancer; Over Cancer; Healthy Control

Keywords

trace elements; endometriosis; endometrial cancer; overian cancer

Outcome Measures

Primary Outcomes (14)

• Serum beryllium (Be) measurment

  Measured beryllium (Be) levels in the serum samples of study group by ICP-MS baseline.

  3 months

• Serum phosphorus (P) measurment

  Phosphorus levels (ppb) in the serum samples of study group by ICP-MS baseline.

  3 months

• Serum vanadium (V) mesurment

  Measured vanadium (V) levels (ppb) in the serum samples of study group by ICP-MS baseline.

  3 months

• Serum chromium (Cr) measurment

  Measured chromium (Cr) levels in the serum samples of study group by ICP-MS baseline.

  3 months

• Serum manganese (Mn) measurment

  Measured manganese (Mn) levels in the serum samples of study group by ICP-MS baseline.

  3 months

• Serum iron (Fe) measurment

  Measured iron (Fe) levels in the serum samples of study group by ICP-MS baseline.

  3 months

• Serum cobalt (Co) measurment

  Measured cobalt (Co) levels in the serum samples of study group by ICP-MS baseline.

  3 months

• Serum nickel (Ni) measurment

  Measured nickel (Ni) levels in the serum samples of study group by ICP-MS baseline.

  3 months

• Serum arsenic (As) measurment

  Measured arsenic (As) levels in the serum samples of study group by ICP-MS baseline.

  3 months

• Serum selenium (Se) measurment

  Measured selenium (Se) levels in the serum samples of study group by ICP-MS baseline.

  3 months

• Serum molybdenum (Mo) measurment

  Measured molybdenum (Mo) levels in the serum samples of study group by ICP-MS baseline.

  3 months

• Serum cadmium (Cd) measurment

  Measured cadmium (Cd) levels in the serum samples of study group by ICP-MS baseline.

  3 months

• Serum antimony (Sb) measurment

  Measured antimony (Sb) levels in the serum samples of study group by ICP-MS baseline.

  3 months

• Serum lead (Pb) measurment

  Measured lead (Pb) levels in the serum samples of study group by ICP-MS baseline.

  3 months

Study Arms (4)

Control group

EXPERIMENTAL

Consists of healthy individuals

Diagnostic Test: Blood Product

Endometriosis group

EXPERIMENTAL

Consists of individuals diagnosed with endometriosis

Diagnostic Test: Blood Product

Overian cancer group

EXPERIMENTAL

Consists of individuals diagnosed with ovarian cancer

Diagnostic Test: Blood Product

Endometrial cancer

EXPERIMENTAL

Consists of individuals diagnosed with endometrial cancer

Diagnostic Test: Blood Product

Interventions

Blood Product DIAGNOSTIC_TEST

5 mL of blood was collected from the right arms of all individuals in 4 different groups. Their serum was obtained.

Control group; Endometrial cancer; Endometriosis group; Overian cancer group

Eligibility Criteria

• Age: 18 Years - 55 Years
• Gender Eligibility Details: Since this study is about gynecological diseases, female participants must be selected.
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Not having received chemotherapy, radiotherapy or immunotherapy in the last three months
• For the endometriosis group: histopathologically or laparoscopically confirmed endometriosis
• For the ovarian cancer group: histopathologically confirmed epithelial ovarian cancer
• For the endometrial cancer group: histopathologically confirmed endometrial adenocarcinoma
• For the control group: healthy individuals who underwent surgery for benign gynecological causes (e.g., myoma, benign cyst) and who were not diagnosed with malignancy/endometriosis

You may not qualify if:

• Chronic systemic diseases (e.g., chronic renal failure, liver disease, severe cardiac disease)
• Diseases that may affect metabolism or trace element levels (e.g., Wilson's disease, hemochromatosis)
• Use of dietary supplements containing minerals or trace elements within the past 6 months
• Environmental or occupational heavy metal exposure (e.g., mining, metallurgy, battery industry workers)
• Pregnancy or breastfeeding
• History of acute infection or inflammatory disease
• History of recurrent surgery or advanced metastatic cancer (as this may alter serum parameters)
• Psychiatric or cognitive disorders that preclude participation in the study

Sponsors & Collaborators

• Cumhuriyet University: lead

Study Sites (1)

sivas Cumhuriyet University

Sivas, Centre, 58146, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Endometriosis; Endometrial Neoplasms

Condition Hierarchy (Ancestors)

Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr.

Model Details: We have four groups in the study. Blood will be drawn from each group only once. No other interventions will be performed.

Study Record Dates

• First Submitted: September 30, 2025
• First Posted: October 7, 2025
• Study Start: April 24, 2025
• Primary Completion: September 29, 2025
• Study Completion: September 29, 2025
• Last Updated: November 24, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)